Author: Customer Service

Total Revenue Expected to be $276 Million  MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results and other business updates for the fourth quarter and year ended December 31, 2025. Preliminary, Unaudited Full-Year 2025 Financial ResultsTotal net revenue expected to be approximately $276 million, with MACI® net revenue of $239.5 million and Burn Care net revenue of $36.5 million Gross margin expected to be 74% and adjusted EBITDA margin expected to be 26% GAAP Net Income profitability expected for the second consecutive year $200 million in cash and investments,...

Increase brings the total number of GPS network providers to 73 via the Company’s real-time freight geolocation module, Fr8Radar HOUSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) — Freight Technologies, Inc. (Nasdaq: FRGT, “Fr8Tech” or the “Company”), a technology-driven logistics company leveraging artificial intelligence and offering a diversified portfolio of AI-enabled software solutions designed to address key inefficiencies in the supply chain, today announced the continued expansion of Fleet Rocket, its cloud-based Transportation Management System (TMS), driven by accelerating adoption of its Fr8Radar GPS integration network. Since October 2025, Fleet Rocket has added 19 new GPS providers, bringing the total number of integrated GPS networks to 73 across the U.S. and Mexico. The increase represents the strongest period of GPS integration...

– Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multiple oncology indications HOUSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), announced it has received a new independent assessment for the absence of cardiotoxicity in subjects treated with Annamycin, bringing the total number of Annamycin treated subjects reviewed by its independent expert to 90. Data from the most recently completed clinical trials’ subjects were made available to an expert in chemotherapy who is affiliated with a leading cancer research institute in assessing cardiotoxicity. After review of certain data, the independent expert concluded that there was...

CEO Highlights Significant Progress Achieved & Outlines Ambitious Plans for 2026 MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced a shareholder update from its Chief Executive Officer and Cofounder, Mr. James Nathanielsz. In this update, Mr. Nathanielsz highlights the significant progress achieved during 2025 and outlines the Company’s ambitious plans for 2026. With strong confidence, Propanc is executing its strategic roadmap for the clinical development of its lead asset, PRP, while further strengthening its scientific platform by expanding into additional therapeutic areas with high unmet medical need...

Company Aligns Communications Strategy with Growing Industry and Investor Interest Detroit, Michigan, Jan. 13, 2026 (GLOBE NEWSWIRE) — Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCID:AITX), a global leader in AI-driven security and productivity solutions, today announced that it has engaged a national public relations firm to expand awareness of the Company across the media, financial markets, and investor community. The engagement is intended to elevate understanding of AITX’s business model, technology leadership, and long term growth strategy as the Company enters its next phase of market visibility. The decision follows a period of expanding operational scale, increased market relevance, and growing interest in the Company’s autonomous security and AI driven solutions. As AITX continues to execute...

Company Remains Fully Committed to Advancing Its Core Intranasal Medical Pipeline, alongside examining new opportunities including in fields of aviation, AI and defense Raanana, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) — Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, recently announced that its Board of Directors has authorized the exploration of strategic investment opportunities in select revenue-generating assets. Polyrizon is focusing its initial efforts on operating companies in high-potential sectors, including defense, aviation, and artificial intelligence (AI). The Company remains fully committed to its core medical device activities, continuing to advance product development, preclinical and clinical studies,...